161 related articles for article (PubMed ID: 11494038)
21. [The effects of genistein on epidermal growth factor receptor mediated signal transduction pathway in human ovarian carcinoma cells lines SKOV3 and its xenograft in nude mice].
Li Y; Mi C; Wu YZ; Yang SF; Yang ZQ
Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):546-9. PubMed ID: 15634453
[TBL] [Abstract][Full Text] [Related]
22. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
[TBL] [Abstract][Full Text] [Related]
23. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.
Bajo AM; Schally AV; Krupa M; Hebert F; Groot K; Szepeshazi K
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3836-41. PubMed ID: 11891317
[TBL] [Abstract][Full Text] [Related]
24. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
25. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
[TBL] [Abstract][Full Text] [Related]
26. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
Westphalen S; Kotulla G; Kaiser F; Krauss W; Werning G; Elsasser HP; Nagy A; Schulz KD; Grundker C; Schally AV; Emons G
Int J Oncol; 2000 Nov; 17(5):1063-9. PubMed ID: 11029513
[TBL] [Abstract][Full Text] [Related]
27. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
[TBL] [Abstract][Full Text] [Related]
28. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
Buchholz S; Seitz S; Schally AV; Engel JB; Rick FG; Szalontay L; Hohla F; Krishan A; Papadia A; Gaiser T; Brockhoff G; Ortmann O; Diedrich K; Köster F
Int J Oncol; 2009 Oct; 35(4):789-96. PubMed ID: 19724914
[TBL] [Abstract][Full Text] [Related]
29. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors.
Wang J; Luo F; Lu JJ; Chen PK; Liu P; Zheng W
Int J Cancer; 2002 Jan; 97(2):163-7. PubMed ID: 11774259
[TBL] [Abstract][Full Text] [Related]
30. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
[TBL] [Abstract][Full Text] [Related]
31. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
32. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
33. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
[TBL] [Abstract][Full Text] [Related]
34. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Nagy A; Schally AV; Emons G
Breast Cancer Res Treat; 2004 Oct; 87(3):255-64. PubMed ID: 15528968
[TBL] [Abstract][Full Text] [Related]
35. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Eur J Cancer; 2005 Sep; 41(14):2196-202. PubMed ID: 16182122
[TBL] [Abstract][Full Text] [Related]
36. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.
Hu YL; Tee MK; Goetzl EJ; Auersperg N; Mills GB; Ferrara N; Jaffe RB
J Natl Cancer Inst; 2001 May; 93(10):762-8. PubMed ID: 11353786
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.
Halmos G; Nagy A; Lamharzi N; Schally AV
Cancer Lett; 1999 Mar; 136(2):129-36. PubMed ID: 10355741
[TBL] [Abstract][Full Text] [Related]
38. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
Milovanovic SR; Monje E; Szepeshazi K; Radulovic S; Schally A
J Cancer Res Clin Oncol; 1993; 119(5):273-8. PubMed ID: 8382705
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Nagy A; Schally AV; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7269-73. PubMed ID: 8692981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
